AstraZeneca and Lilly to team Cyramza with anti-PD-L1
This article was originally published in Scrip
Executive Summary
AstraZeneca and Eli Lilly have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Lilly's VEGF receptor 2 inhibitor Cyramza (ramucirumab) in a Phase I study advanced solid tumors. The alliance is one of a growing number looking at combining immune-oncology products with other more established targeted anticancers. "The development of immune checkpoint inhibitors has been one of the more exciting research advancements in recent oncology history, but it is going to be even more interesting to see how these inhibitors can be combined with other proven targeted therapies," said Dr Richard Gaynor senior vice-president, product development and medical affairs at Lilly Oncology. "This collaboration represents the next wave of immuno-oncology research by bringing together two innovative medicines."
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.